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Objective: Wound repair is a complex integration of dynamic processes mediated by
humeral messages controlling the levels of cytokines, growth factors, and matrix met-
alloproteinases in the wound space. Isolated growth factors and growth factor combi-
nations have been used to accelerate wound healing with limited success. A cellular
cytokine solution can be collected by harvesting the proteins released from amnion-
derived multipotent progenitor cells. The purpose of this study was to compare levels
of cytokines/growth factors in amnion-derived cellular cytokine solution with physio-
logical levels reported in the medical literature. Methods: Amnion-derived multipotent
progenitor cells were grown to confluency, and the proteins secreted were characterized
by qualitative and quantitative analysis. These results were compared with physiologic
levels reported in the medical literature. Results: The results demonstrated that amnion-
derived cellular cytokine solution contained physiologic levels of cytokines relevant to
wound healing, including platelet-derived growth factor, vascular endothelial growth
factor, angiogenin, transforming growth factor β2, tissue inhibitor of metalloproteinase-
1, and tissue inhibitor of metalloproteinase-2. The ranges (mean ± standard deviation)
were as follows: platelet-derived growth factor, 86 ± 33 pg/mL; vascular endothelial
growth factor, 5.7 ± 1.5 ng/mL; angiogenin, 1.0 ± 0.33 ng/mL; transforming growth
factor β2, 500 ± 330 pg/mL; tissue inhibitor of metalloproteinase-1, 530 ± 140 ng/mL;
and tissue inhibitor of metalloproteinase-2230 ± 40 ng/mL. These levels are compara-
ble with the physiologic levels reported in the literature. Conclusions: The physiologic
levels of cytokines important to healing found in amnion-derived cellular cytokine solu-
tion suggest that amnion-derived cellular cytokine solution may be of benefit in healing
certain acute and chronic wounds.
Wound repair is a complex integration of dynamic interactive processes involving
cell-cell and cell-matrix interactions mediated by humoral messengers.1 These messen-
gers that control the various cellular processes include cytokines, growth factors, and
matrix metalloproteinases (MMPs).2 They regulate many of the processes that are cru-
cial for wound healing, including chemotactic migration of inflammatory cells; mitosis of
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fibroblasts, keratinocytes, and vascular endothelial cells; neovascularization; and synthesis
and degradation of extracellular components.3
Theliteratureisrepletewithexamplesofeffectsofexogenousapplicationofcytokines
in animal models of both acute and chronic wounds.4 In all of these animal models, it has
been suggested that wound healing would be enhanced by topical application of cytokines.
Clinical trials have been performed for many of the cytokines and/or growth factors in
both acute and chronic wounds.4 Unfortunately, the results of these trials have been largely
disappointing, with only a single growth factor, platelet-derived growth factor (PDGF)-
BB, being approved by the US Food and Drug Administration, and that was for a single
indication, diabetic foot ulcers.
There are several reasons why topical cytokine/growth factor therapy has failed.5
These include application of a single growth factor, application in large pharmaceutical
doses, degradation of the peptide by proteases, and improper preparation of the wound.
The application of a single growth factor may seem ill conceived. Normal wound healing
is accomplished by a combination of cytokines, and they occur in a “natural” cascade.6
Only a few attempts of combination or sequential cytokine therapy have been reported.
Knighton et al7 used an autologous platelet releasate labeled as platelet-derived wound
healing factors (PDWHF). Steed et al8 reported similar success with PDWHF. An extract
of milk that contained insulin-like growth factor-1, PDGF, basic fibroblast growth factor,
and transforming growth factor β (TGF-β) has been reported to be effective in accelerating
healing in animal models.9 The first wound healing clinical trial using sequential topically
applied cytokines to accelerate healing was reported in 2000.10
The possible combinations or sequences for cytokines are endless. Moreover, attempt-
ing to determine levels of the various factors to include is formidable. The concept behind
PDWHF was that the platelet releasate contained its cytokines in physiologic levels. Un-
fortunately, these levels were never critically examined, nor determined to be physiologic.
Stem cells and stem cell–like multipotent cells are known to produce cytokine growth fac-
tors that serve as mediators to the cellular processes of the wound healing scheme.11 In a
recent article, Xing et al12 demonstrated that amnion-derived multipotent progenitor cells
increased gain of incisional breaking strength and decreased the incidence and severity of
acute wound failure.12 They postulated that 1 possible mechanism for their results could be
the effect of the cocktail of secreted cytokines from the cells.
Cells in culture secrete factors, which may provide support to or affect the growth, dif-
ferentiation, and protein production of other cells. These factors include cytokines, growth
factors, chemokines, hormones, proteins, extracellular matrix, vesicles, receptors, antibod-
ies, inhibitors, and granules. The purpose of this study was to determine the presence and
levelsofcytokines/growthfactorsinamnion-derivedcellularcytokinesolution(ACCS)and
review the literature to determine the natural or physiological levels of these peptides in
normally healing wounds.
MATERIALS AND METHODS
Full-term placentas donated for research using an “honest broker” system to maintain
anonymitywereobtainedfromscheduledcaesariansectiondeliverieswithhospitalapproval.
All placentas were devoid of identifiers when received. Amnion-derived multipotent
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progenitor cells were grown to confluency, and using proprietary techniques, the super-
natant was harvested. This secreted product was labeled ACCS. The proteins in the ACCS
were characterized by both qualitative and quantitative analysis.
Qualitative analysis
ACCSsampleswereshippedovernightondryicetoRayBiotech(Norcross,Ga)foranalysis
intheHumanGrowthFactorAntibodyArray1,HumanMatrixMetalloproteinaseAntibody
Array 1, and Human Cytokine Antibody Arrays 6, 7, and 8.
Quantitative analysis
ACCS samples were shipped overnight on dry ice to Pierce Biotechnology (Woburn, Mass)
for analysis in the Multiplex Custom Searchlight Human Protein Antibody Array.
Samples were also sent to RayBiotech (Norcross, Ga) for analysis in the Custom Hu-
man Cytokine Antibody Array. In-house quantitative measurements were conducted using
RayBiotech’s RayBio Human ELISA kits for the cytokines VEGF, PDGF-BB, angiogenin,
TGF-β2, TIMP-1, and TIMP-2. Detectable limits of the assays were the following: VEGF,
20 pg/mL; PDGF-BB, 2 pg/mL; angiogenin, 1.5 pg/mL; TGF-β2, 15 pg/mL; TIMP-1,
40 pg/mL; and TIMP-2, 10 pg/mL. ACCS samples were assayed in duplicate. Results were
inthelinearportionofthestandardcurve.Othercytokinesandgrowthfactorsweredetected
but not quantified.
To determine the physiologic levels of cytokines and growth factors in humans, the
literature was reviewed by searching PubMed, MEDLINE, and the Cochrane Database of
Systematic Reviews.
RESULTS
ACCS was characterized by assaying for physiologically relevant cytokines, including
PDGF, VEGF, angiogenin, TGF-β2, TIMP-1, and TIMP-2. Cytokines are secreted from
these cells in the physiologic range reported in the literature.
Results are as follows (see Fig 1):
Cytokine Level in ACCS Literature
PDGF 53–119 pg/mL 20–1,700 pg/mL (references 13–18)
VEGF 4.2–7.2 ng/mL 0.2–20 ng/mL (references 17–25)
Angiogenin 0.67–1.33 ng/mL 0.2–334 ng/mL (references 26–30)
TGF-β2 0.17–0.83 ng/mL 0.3–4.2 ng/mL (references 15, 16, 31–33)
TIMP-1 390–670 ng/mL 56–373 ng/mL (references 34–37)
TIMP-2 190–270 ng/mL 10–208 ng/mL (references 38–40)
LITERATURE REVIEW
PDGF levels have been measured and reported in many different fluids in both normal and
diseased tissues. Some reports measure total PDGF, whereas others measure the PDGF-BB
homodimerorthePDGF-ABheterodimer.Inmoststudies,PDGFwaspresentinpicograms
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Figure 1. Cytokine, levels in amnion-derived cellular cytokine solution (ACCS) literature. Pools
are made up of 9 (pool 1), 8 (pools 2 and 4), or 4 (pool 3) individual ACCS harvests. The solid
bar shows the average and SD of the ACCS harvests for the 29 individual placentas contributing to
the pools. TIMP-1 indicates tissue inhibitor of metalloproteinase-1; TGF-β2, transforming growth
factor β2; TIMP-2, indicates tissue inhibitor of metalloproteinase-2; PDGF-BB, platelet-derived
growth factor-BB; and VEGF, vascular endothelial growth factor.
per milliliter, although some studies found amounts in nanogram. The physiologic range
chosen here was from studies sampling serum in healthy patients (1700 pg/mL),13 normal
sinusfluid(311pg/mL),14healingandnonhealingankleulcers(133pg/mLand97pg/mL),15
burnblisterfluid(154pg/mL),16 andsurgicaldrains(20–180pg/mL)17 andwounddrainage
following colorectal procedures (817 pg/mL, 74–1015 pg/mL).18 PDGF-BB level in ACCS
is within the normal physiologic range reported in the literature.
VEGF levels were also measured in many different tissues, both healthy and diseased,
at many different time points. In most cases, the levels were in amounts of nanograms per
milliliter. VEGF level was low in serum (0.2 ng/mL).19 This would be anticipated because
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there is little reason physiologically why an angiogenesis factor should circulate through
the blood at an elevated level under normal circumstances. VEGF levels were the same
in drainage from breast wounds, whether benign or malignant disease (1–3.1 ng/mL).18,20
SimilarlevelsofVEGFwerefoundinfluidfromherniarepairs,surgicaldrains,andseromas
(1.2–20 ng/mL),17,21 as well as in wounds following colorectal surgery (0.8–2.8 ng/mL)22
andthyroidcystswhichspontaneouslyregressed(4.3ng/mL).23 Inmostcases,VEGFlevels
weresimilartoACCS.VeryhighlevelsofVEGFwerefoundinwoundfluidfollowinghernia
repair with mesh (160–330 ng/mL),24 but these levels were not considered physiologic and
notincludedinthetablebecausetheymayhavebeenassociatedwiththeprostheticmaterial.
VEGFlevelwasalsomuchhigherinthegranulationtissueofhealingsacraldecubitusulcers,
well above the physiologic range (1100 ng/mL)25.
Angiogenin levels were measured in a control population of several different studies.
Levels of angiogenin in ACCS were at the lower end of the physiologic ranges reported
(0.2–334ng/mL).26–29 Angiogeninlevelsweremeasuredinamnioticfluidandweregreater
than ACCS (22–32 ng/mL).30
TGF-β2 plays a critical role in the healing process and scarring. TGF-β2w as mea-
sured in split-thickness skin grafts (0.03 ng/mL)31 and in healing and nonhealing wounds
(0.02–0.03 ng/mL).15 These levels were about the same in burn blisters (0.04 ng/mL)16 and
breast cysts (0.1–0.3 ng/mL).32 In each of these cases, the levels of TGF-β2 measured were
in the range found in ACCS. The levels of TGF-β2w ere much high in the wound fluid of
patients following reduction mammoplasty, an operation with much soft tissue dissection
(16–38 ng/mL).33
TIMP-1 and TIMP-2 have been measured as controls in 2 studies (373 ng/mL and
106 ng/mL).34,35 TIMP-1 level has been shown to be higher in patients with pressure ulcers
characterized as “good healers” (170 ng/mL)36 than “poor healers” (56 ng/mL).36 TIMP-1
level is much higher in wound drainage when negative pressure wound therapy is used
(1493 ng/mL),37 perhaps related again to stimulation by foreign body. For this reason, this
level was not considered to be physiologic. TIMP-1 levels in ACCS are at the upper limit of
normal or somewhat above. TIMP-2 level was much higher in healthy controls (49 ng/mL
and 136–208 ng/mL)38,39 than patients with diabetes (10 ng/mL).40 Thus, ACCS levels of
both TIMP-1 and TIMP-2 are at the upper limit of the physiologic range and above.
DISCUSSION
The purpose of this work was to determine the levels of certain cytokines or growth factors
released into the supernatant of cultures of amnion-derived multipotent progenitor cells.
These levels were then compared with physiologic levels measured in humans and reported
in the literature. An extensive review of the literature yielded very few direct measurements
of cytokines or growth factors in normal tissues.
The data that are available, in general, and are reported for individual cytokines or
growthfactorsisolatedfromasinglesite.Aphysiologicgrowthfactorsolutioncontaininga
combinationofgrowthfactorshasbeenreportedasPDWHF.Thesegrowthfactorshavebeen
harvested from platelets by centrifugation of platelets from whole blood, then releasing the
contents of the α-granules of the platelet with thrombin. The “platelet releasate” was used
clinically by diluting the growth factor preparation with buffered saline. The concentration
of growth factors is not “physiologic” in contrast with the concentrations measured in
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ACCS. The concentration in PDWHF depends on the amount of buffered saline added to
the releasate. There have been several reports of successful treatment of lower-extremity
wounds with PDWHF, but the concentration of growth factors was much higher than the
physiologic concentration measured in ACCS.7,8
One of the growth factors in ACCS, PDGF-BB, has been made through a recombi-
nant DNA technique. It has been used in the healing of diabetic foot ulcers in randomized
prospective blinded trials and found to be of benefit. It is marketed as becaplermin (Re-
granex). Packaged in a concentration of 0.1% or 0.1 mg/mL, PDGF is present in 1 million
times the concentration found in ACCS. Of note, there have been no reported cases of
toxicity from systemic absorption of becaplermin and no antibodies to becaplermin were
found in patients exposed to this drug applied topically.
VEGF, angiogenin, and to some degree, PDGF, are angiogenesis factors. VEGF is a
signaling protein involved in stimulating the growth of new blood vessels. In hypoxia, cells
may produce hypoxia-inducible factor, which stimulates the release of VEGF, which binds
to VEGF receptors, in turn leading to angiogenesis. Angiogenesis is essential to wound
healing in every clinical setting. Angiogenin is also a polypeptide involved in angiogenesis.
It triggers angiogenesis by inducing the proliferation of endothelial cells. PDGF regulates
the growth and replication of cells and, as such, plays a pivotal role in wound healing. It
stimulates angiogenesis but plays a role in many other functions including cell proliferation
andcellmigration.Angiogenesisfactorsmaypromotetumorgrowth;VEGFandangiogenin
levels are low in ACCS.
TGF-β controls proliferation and differentiation of cells. Many cells make TGF-β and
most have receptors for this protein. TGF-β plays a role in hormone secretion and wound
healing.
TIMPs are natural inhibitors of MMPs, a group of peptidases, which degrade extra-
cellular matrix. MMPs degrade growth factors; TIMPs counteract that process. TIMP also
promotes cell proliferation and many prevent apoptosis. TIMP-1 binds to proMMP-9 and
TIMP-2bindstoproMMP-2.MMPshavebeenshowntoinhibithealinganddegradegrowth
factors. Inhibition or inactivation of MMPs should facilitate healing.
The study of normal cytokine levels in animals is necessary if one is to determine
the direction and magnitude of change of these proteins in pathological conditions. Tissues
can be sampled and animals can be sacrificed to allow for these measurements. Invasive
monitoringandsamplingcanbeperformedwithlittleregard,tosomedegree,forsterilityand
the consequences to the laboratory animal. These issues become critical when attempting
to measure the cytokine levels in humans. First, there is the issue of scientific merit. An
investigator must convince himself or herself, the patient, and the institutional review board
that the risk to the individual of measuring these levels is justified. The challenges are a
bit different when one attempts to measure these levels in disease states. The levels can be
determined by the study of tissue, blood, body fluids, tumors, cysts, wounds, seromas, and
wound drainage. Cytokines can be measured in both the pathological tissue and the normal
tissue adjacent to the abnormality. The issue in this circumstance is, of course, whether the
neighboring tissue in a diseased patient is truly normal.
If one samples over time, cytokine levels change. The question then becomes what
measurement is the physiological value versus a pathophysiological level.
All of the issues discussed here were encountered when attempting to determine the
physiologic levels of cytokines to compare with the levels secreted by amnion-derived
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multipotent progenitor cells. The first issue is which of the many cytokines known to be
present should be studied in depth. Some of the factors measured in ACCS are known to be
important to wound healing. These include PDGF, VEGF, angiogenin, TGF-β2, TIMP-1,
and TIMP-2. The levels were measured by antibody array, enzyme-linked immunosorbent
assay, and multiplex and mass spectroscopy.
Eachofthetechniquesyieldedasomewhatdifferentresult.Differencesinculturetech-
niques and conditions also lead to some differences in cytokine levels. The measurements
were, however, within the same magnitude even when measured by different methods.
The greater challenge was to decide what constituted a “physiologic” level. Cytokines
and growth factor levels were measured in normal tissues including blood. In some cases,
the“normal”tissuelevelsweretakenfrompatientswithillnesses—werethesetrulynormal?
Inothercases,thelevelsweretakenfromdiseasedtissues,butmostwerefromnormalphys-
iologic states and processes including wounds, wound drainage, cysts, and fluid collections
such as seromas. Moreover, the levels were measured at different stages of wound healing
in patients with problems of different severity. Our approach was to decide the “normal or
physiologic range” by looking for normal tissues or tissues closest to normal in patients
with the least amount of problems.
There was reasonably good correlation between levels of cytokines measured in hu-
mans and the level of cytokines found to be secreted by the amnion-derived multipotent
progenitor cells. In most cases, the levels measured in ACCS were near the lower end of the
physiologic range, except for TIMP-1 and TIMP-2, which were at the upper limit. These
physiologic levels of cytokines important in wound healing lead us to believe that an ACCS
may be of benefit in healing acute and chronic wounds when used in a context of good
clinical care.
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